NCT04200443 - Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

October 7, 2025

Study Completion Date

October 7, 2025

Conditions

Metastatic LeiomyosarcomaMetastatic Soft Tissue SarcomaStage III Uterine Corpus Leiomyosarcoma AJCC v8Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8Stage IV Uterine Corpus Leiomyosarcoma AJCC v8Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8Unresectable LeiomyosarcomaUnresectable Soft Tissue Sarcoma

Interventions

DRUG

Cabozantinib

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Temozolomide

Given PO

Trial Locations (5)

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53226

Medical College of Wisconsin, Milwaukee

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER